• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Pharmaceutical Industry Chief Kåre Schultz Joins Hims & Hers Board

    7/22/24 5:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care
    Get the next $HIMS alert in real time by email

    Bringing experience from Novo Nordisk and Teva Pharmaceutical Industries, Schultz joins the Hims & Hers Board of Directors to help the company increase access to health and wellness solutions

    Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Kåre Schultz to the company's Board of Directors.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240722754740/en/

    Bringing experience from Novo Nordisk and Teva Pharmaceutical Industries, Schultz joins the Hims & Hers Board of Directors to help the company increase access to health and wellness solutions. (Photo: Business Wire)

    Bringing experience from Novo Nordisk and Teva Pharmaceutical Industries, Schultz joins the Hims & Hers Board of Directors to help the company increase access to health and wellness solutions. (Photo: Business Wire)

    Kåre Schultz brings a unique global perspective on the healthcare and pharmaceutical industries from his decades of leadership experience at several international organizations, including Teva Pharmaceutical Industries, Lundbeck, and Novo Nordisk. Mr. Schultz spent over 25 years at Novo Nordisk, where he served in many capacities, most notably as President and COO as the company established itself as a leading company in diabetes care. As CEO of Teva Pharmaceutical Industries, Mr. Schultz streamlined operations to focus the company on its core strengths in generics and specialty medicines. Mr. Schultz also served as CEO of Lundbeck, where he helped position the company as a leader in the pharmaceutical industry.

    "We are in a transformative moment for healthcare with the opportunity to make life-changing treatments accessible to all who need it. Kåre's experience gives us an incredible wealth of expertise as we bring together the most valuable elements of clinical excellence, healthcare, and technology to redefine health and wellness for our customers," said Andrew Dudum, CEO and co-founder of Hims & Hers. "We're honored to have Kåre join us to share his perspective and leadership as we continue to serve more customers across our platform."

    "Hims & Hers is on a trajectory to upend the healthcare industry," said Kåre Schultz. "In my long career in the pharmaceutical industry, this is the first company I have seen that is leveraging today's modern tools to truly break down barriers and change the status quo of how people access the health solutions they need to live their fullest lives. I'm thrilled to be a part of this journey."

    Mr. Schultz joins leaders from across industries on the Hims & Hers Board of Directors including: former CEO of the Cleveland Clinic, Dr. Toby Cosgrove; tech industry leader, Christopher Payne; US regulatory and foreign policy expert, Anja Manuel; former Chief Medical Officer of Walgreens and current Chief Medical Officer of Hims & Hers, Patrick Carroll; former CFO of Netflix, David Wells; consumer retail expert, Christiane Pendarvis; and former Nike and Sony marketing executive, Andrea Perez.

    About Hims & Hers Health, Inc

    Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That's why we're building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalized care designed for results. For more information, please visit www.hims.com and www.forhers.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240722754740/en/

    Get the next $HIMS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HIMS

    DatePrice TargetRatingAnalyst
    4/29/2025$30.00Buy → Hold
    TD Cowen
    2/18/2025$42.00 → $60.00Overweight → Equal-Weight
    Morgan Stanley
    1/10/2025$24.00 → $25.00Neutral → Sell
    Citigroup
    1/7/2025$35.00Buy
    BTIG Research
    12/17/2024$42.00Overweight
    Morgan Stanley
    11/14/2024Buy → Underperform
    BofA Securities
    8/22/2024$24.00Buy
    Needham
    8/9/2024Outperform → In-line
    Imperial Capital
    More analyst ratings

    $HIMS
    Leadership Updates

    Live Leadership Updates

    See more
    • Hims & Hers Appoints AI Expert and Former President and CTO at Cruise as Chief Technology Officer

      Mo Elshenawy joins as the company doubles down on the role AI will play in the next generation of healthcare. Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Mo Elshenawy, a proven technology executive with deep expertise in artificial intelligence and large-scale infrastructure, as the company's new Chief Technology Officer. His appointment marks a key milestone as Hims & Hers accelerates its vision to build the next-generation healthcare platform, powered by AI and designed to deliver deeply personalized, accessible care at scale. This press release features multimedia. View the full release here: https://www.businesswire

      5/8/25 6:50:00 AM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Hims & Hers Appoints Global Operations Expert and Amazon Veteran as Chief Operations Officer

      Bringing nearly 20 years of global experience at Amazon, Nader Kabbani is joining the executive leadership team to help the company further innovate on the delivery of affordable, seamless personalized care in the U.S. and globally. Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Nader Kabbani as Chief Operations Officer.1 A seasoned executive known for scaling trusted consumer and healthcare logistics businesses, Kabbani will oversee operations as the company expands access to personalized care for millions more individuals. This press release features multimedia. View the full release here: https://www.businesswire.com/ne

      5/5/25 9:01:00 AM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Define Ventures Appoints Carolyn Magill as Venture Partner

      The former Aetion and Remedy Partners CEO joins Define to further drive innovation across provider, payer, and pharmaceutical sectors SAN FRANCISCO, March 11, 2025 /PRNewswire/ -- Define Ventures, one of the largest venture capital firms focused on early-stage health tech companies, today announced that Carolyn Magill, former CEO of Aetion, has joined the firm as venture partner. Magill, leveraging her 25 years of invaluable experience scaling companies and fostering innovation within payer, provider, and pharmaceutical organizations, will partner with Define founders to scale their companies and become category-defining companies.

      3/11/25 5:30:00 AM ET
      $EVH
      $HIMS
      $LVGO
      Other Consumer Services
      Consumer Discretionary
      Medical/Nursing Services
      Health Care

    $HIMS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Baird Melissa exercised 33,333 shares at a strike of $2.43 and sold $1,867,376 worth of shares (33,333 units at $56.02) (SEC Form 4)

      4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

      5/13/25 5:07:27 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Chief Legal Officer Boughton Soleil sold $181,160 worth of shares (3,235 units at $56.00), decreasing direct ownership by 2% to 156,427 units (SEC Form 4)

      4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

      5/13/25 5:07:16 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Chief Legal Officer Boughton Soleil sold $97,695 worth of shares (3,236 units at $30.19), decreasing direct ownership by 2% to 159,662 units (SEC Form 4)

      4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

      4/30/25 6:01:31 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care

    $HIMS
    SEC Filings

    See more
    • Hims & Hers Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities

      8-K - Hims & Hers Health, Inc. (0001773751) (Filer)

      5/13/25 5:23:44 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Hims & Hers Health Inc. filed SEC Form 8-K: Other Events

      8-K - Hims & Hers Health, Inc. (0001773751) (Filer)

      5/9/25 7:00:17 AM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • SEC Form 10-Q filed by Hims & Hers Health Inc.

      10-Q - Hims & Hers Health, Inc. (0001773751) (Filer)

      5/5/25 4:17:34 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care

    $HIMS
    Financials

    Live finance-specific insights

    See more
    • Hims & Hers Health, Inc. Reports First Quarter 2025 Financial Results

      Revenue of $586.0 million, up 111% year-over-year in Q1 2025 Net income of $49.5 million; Adjusted EBITDA of $91.1 million in Q1 2025 Subscribers grew to 2.4 million, up 38% year-over-year in Q1 2025 Affirms full year 2025 revenue guidance of $2.3 billion to $2.4 billion and raises Adjusted EBITDA guidance to a range of $295 million to $335 million Introduces 2030 targets of at least $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the first quarter ended March 31, 2025, in a shareholder letter that is posted at investors.him

      5/5/25 4:05:00 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Hims & Hers to Announce First Quarter 2025 Financial Results on May 5, 2025

      Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, today announced that it will report first quarter 2025 financial results after the market closes on Monday, May 5, 2025. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referencing conference ID 1704296. A live audio webcast will be available at https://investors.hims.com and will be archived for one year. Upcoming Conference Participation Hims & Hers also announced that members of the company's management team

      4/14/25 4:05:00 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results

      Revenue of $1.5 billion, up 69% year-over-year in 2024 Net income of $126 million; Adjusted EBITDA of $177 million in 2024 Subscribers grew to 2.2 million, up 45% year-over-year in 2024 Provides Q1 and full year 2025 guidance, with full year 2025 revenue in the range of $2.3 billion to $2.4 billion and Adjusted EBITDA in the range of $270 million to $320 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the fourth quarter and full year ended December 31, 2024 in a shareholder letter that is posted at investors.hims.com. "2024 was a fantastic year at Hims and Hers as we con

      2/24/25 4:05:00 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care

    $HIMS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Hims & Hers Health, Inc. Prices Upsized $870.0 Million Convertible Senior Notes Offering to Accelerate Global Expansion and Utilization of AI in Healthcare

      Proceeds intended to support Hims & Hers' global expansion through organic growth and strategic acquisitions, while also fueling deeper investment in AI, diagnostics, and personalized treatments to scale access and meet rising demand for high-quality, personalized care Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS) today announced the pricing of its offering of $870,000,000 aggregate principal amount of 0.00% convertible senior notes due 2030 (the "notes") in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The offering size was increased

      5/8/25 10:25:00 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Hims & Hers Health, Inc. Announces Proposed Convertible Senior Notes Offering to Accelerate Global Expansion and Utilization of AI in Healthcare

      Proceeds intended to support Hims & Hers' global expansion through organic growth and strategic acquisitions, while also fueling deeper investment in AI, diagnostics, and personalized treatments to scale access and meet rising demand for high-quality, personalized care Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS) today announced its intention to offer, subject to market and other conditions, $450 million aggregate principal amount of convertible senior notes due 2030 (the "notes") in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Him

      5/8/25 7:57:00 AM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Hims & Hers Appoints AI Expert and Former President and CTO at Cruise as Chief Technology Officer

      Mo Elshenawy joins as the company doubles down on the role AI will play in the next generation of healthcare. Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Mo Elshenawy, a proven technology executive with deep expertise in artificial intelligence and large-scale infrastructure, as the company's new Chief Technology Officer. His appointment marks a key milestone as Hims & Hers accelerates its vision to build the next-generation healthcare platform, powered by AI and designed to deliver deeply personalized, accessible care at scale. This press release features multimedia. View the full release here: https://www.businesswire

      5/8/25 6:50:00 AM ET
      $HIMS
      Medical/Nursing Services
      Health Care

    $HIMS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

      SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

      11/12/24 3:52:47 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

      SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

      11/4/24 1:33:02 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

      SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

      11/4/24 12:09:24 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care

    $HIMS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Manuel Anja bought $132,260 worth of shares (5,000 units at $26.45) (SEC Form 4)

      4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

      11/14/24 4:57:45 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Payne Christopher D bought $1,951,763 worth of shares (110,000 units at $17.74) (SEC Form 4)

      4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

      5/22/24 4:16:26 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care

    $HIMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Hims & Hers Health downgraded by TD Cowen with a new price target

      TD Cowen downgraded Hims & Hers Health from Buy to Hold and set a new price target of $30.00

      4/29/25 8:05:51 AM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Hims & Hers Health downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Hims & Hers Health from Overweight to Equal-Weight and set a new price target of $60.00 from $42.00 previously

      2/18/25 7:09:28 AM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Hims & Hers Health downgraded by Citigroup with a new price target

      Citigroup downgraded Hims & Hers Health from Neutral to Sell and set a new price target of $25.00 from $24.00 previously

      1/10/25 7:53:16 AM ET
      $HIMS
      Medical/Nursing Services
      Health Care